


Supplementary Material

| | |
|---|----------|
| Supplementary Results | 2 |
| Supplementary Figure 1. Flow chart describing the study population creation steps | 2 |
| Supplementary Figure 2A. Weekly number of second dose recipients by dosing interval for community-dwelling adults aged 16-69 years in Ontario, Canada | 3 |
| Supplementary Figure 2B. Weekly number of second dose recipients by dosing interval for community-dwelling adults aged ≥ 70 years in Ontario, Canada | 4 |

Supplementary Results

Supplementary Figure 1. Flow chart describing the study population creation steps




^aCommunity-dwelling adults are individuals who were not residing in a long-term care facility as of 14 December 2020.

^bFor our main analysis, we included severe outcomes (COVID-19 hospitalizations or deaths) recorded in CCM (Public Health Case and Contact Management) database only.

^cFor cases with multiple occurrences of the same outcome, we selected the first occurrence. For those considered as controls, we randomly selected one negative test during each subperiod. The test-negative controls for the 'severe outcome' study population were the same as the controls from the 'symptomatic infection' study population. Study populations are non-mutually exclusive.

Supplementary Figure 2A. Weekly number of second dose recipients by dosing interval for community-dwelling adults aged 16-69 years in Ontario, Canada



Supplementary Figure 2B. Weekly number of second dose recipients by dosing interval for community-dwelling adults aged ≥ 70 years in Ontario, Canada

